In a multicenter trial, 259 young adults (15-49 years) with newly diagnosed acute myeloid leukemia (AML) were first randomized to receive a timed-sequential induction regimen given either alone (135 patients) or concomitantly with granulocyte-macrophage colony-stimulating factor (GM-CSF) (124 patients). Patients reaching complete remission (CR) were then randomized to compare a timed-sequential consolidation to a postremission chemotherapy including four cycles of highdose cytarabine followed by maintenance courses. In the appropriate arm, GM-CSF was given concurrently with chemotherapy during all cycles of consolidation. CR rates were significantly better in the GM-CSF arm (88 vs 78%, Po0.04), but did not differ after salvage. Patients receiving GM-CSF had a higher 3-year event-free survival (EFS) estimate (42 vs 34%), but GM-CSF did not impact on overall survival. Patients with intermediate-risk cytogenetics benefited more from GM-CSF therapy (P ¼ 0.05) in terms of EFS than patients with other cytogenetics. This was also confirmed when considering only patients following the second randomization, or subgroups defined by a prognostic index based on cytogenetics and the number of courses required for achieving CR. Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML.
Introduction
Most of the younger adults with acute myeloid leukemia (AML) are treated with curative intent. Long-term analysis of the acute leukemia French association (ALFA)-9000 trial was recently published. 1 This trial was conducted in adult AML patients aged 65 or younger, with the aim to randomly compare double induction or timed-sequential induction to a standard induction chemotherapy comprising 7 days of standard-dose cytarabine and 3 days of daunorubicin at the high dosage of 80 mg/m 2 /day.
The same consolidation chemotherapy, which included another course of timed-sequential chemotherapy (TSC), was administered to remitters in the three induction arms. Complete remission (CR) proportion, treatment-related mortality and relapse-free interval were not significantly higher in the more intensive arms. However, relapse-free interval was significantly improved in patients receiving TSC when analyzing patients younger than 50. In vitro, the simultaneous exposure of leukemic cells to chemotherapy and hematopoietic growth factors referred to as growth-factor priming increases the susceptibility of the cells to killing by chemotherapy. [2] [3] [4] [5] [6] Only a few randomized studies have investigated the impact of priming with growth factors in first-line therapy using granulocyte colony-stimulating factor (G-CSF) [7] [8] [9] [10] or granulocyte-macrophage colony-stimulating factor (GM-CSF). [11] [12] [13] GM-CSF priming has been negative in older adults, 11, 13 but there was one positive trial with G-CSF in younger adults. 9 In a randomized double-blind study of the administration of GM-CSF in association with induction TSC in relapsing patients, we previously showed that time to progression tended to be longer in the GM-CSF group. 14 We report here a multicenter trial (ALFA-9802), initiated in 1998, in which patients were randomized at baseline to receive or not GM-CSF during TSC induction and consolidation chemotherapy cycles, with the aim to assess whether priming with a hematopoietic growth factor could improve event-free survival (EFS) in young adults with newly diagnosed AML.
Patients and methods

Patients
Patients aged 15-50 years with a morphologically proven diagnosis of AML according to the French-American-British (FAB) classification [15] [16] [17] and not previously treated for their disease were eligible in absence of severe (World Health Organization grade X3) organ failure. 18 Bone marrow morphology was centrally reviewed. Patients with AML-M3 were not eligible. Patients with a secondary AML or another active cancer were not eligible. The study was approved by the ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. All participants gave their written informed consent.
Risk classification
Cytogenetic studies on pretreatment bone marrow samples were performed at diagnosis using standard banding techniques and classification according to the International System of Human Cytogenetic Nomenclature. 19 Two factors were combined to give three risk groups: good (favorable cytogenetics and response after one course of chemotherapy), poor (adverse cytogenetics or patients who had obtained CR after salvage therapy), standard (neither good nor poor).
Treatments
Patients were randomly assigned to receive GM-CSF (arm A) or no GM-CSF (arm B) during all induction and consolidation courses of chemotherapy ( Figure 1 ). GM-CSF (Leucomax, recombinant human GM-CSF from Escherichia coli, Schering Plough, Kenilworth, NJ, USA) was given at a dose of 5 mg/kg/day intravenously (i.v.) over 6 h, from day 1 through the last day of chemotherapy of each course. Induction chemotherapy consisted of a TSC including a first sequence combining daunorubicin, 80 mg/m 2 /day i.v. on days 1-3 and cytarabine, 500 mg/m 2 /day i.v. over the same period. The second sequence, administered after 4-day free interval, consisted of mitoxantrone, 12 mg/m 2 /day, i.v. on days 8 and 9 and cytarabine, 500 mg/m 2 /12 h on days 8-10. The administration of GM-CSF was postponed in the event of initial leukocytosis X50 Â 10 9 /l until leukocyte count was below 50 Â 10 9 /l. In these cases, pretreatment by hydroxyurea was recommended. In all patients, treatment by GM-CSF could be temporary interrupted if leukocytosis reached 20% more than its initial value and reintroduced when leukocytosis decreased to its initial value. Patients who did not achieve CR after the first course could be given salvage chemotherapy combining cytarabine, 3 g/m 2 /12 h i.v. on days 1, 3, 5, 7, with amsacrine, 100 mg/m 2 /day i.v. on days 1-3. Allogeneic stem cell transplantation (SCT) was performed after CR achievement if a suitable donor was available in the presence of at least one risk factor: initial leukocytosis 4100 Â 10 GM-CSF priming in younger adults with AML X Thomas et al tion after 11/2000 and systematically received the CALGB-like consolidation treatment. Central nervous system prophylaxis with intrathecal (i.t.) chemotherapy (six i.t. administrations combining cytarabine with methylprednisolone and methotrexate) was performed in patients with chromosome 16 abnormality and in patients with initial leukocytosis 4100 Â 10 9 /l. 1 
Response criteria
Response was evaluated just before the onset of the first consolidation course. Standard National Cancer Institute criteria were used to define CR. 24 Patients alive after induction or induction and salvage, but not reaching CR criteria were considered as patients with resistant disease. Induction deaths were defined as deaths occurring between the onset of induction chemotherapy and evaluation of induction or induction/salvage chemotherapy.
Statistical analysis
Random assignment of patients was stratified by center for the first randomization and also by initial induction arm for the second randomization. Reasons for discontinuing participation in the study were noncompliance of the patient, no CR after salvage regimen, excessive extramedullary drug toxicity, deaths, relapse, major protocol violation or lost to follow up. The planned accrual was 344 patients but was limited to 262 following the definitive interruption of GM-CSF production by Schering Plough in November 2003. The primary end point was EFS, which was calculated from the date of first randomization, with CR achievement failures, deaths during induction or in first CR and relapses included as events. We initially planned to enroll patients over a period of 5 years, with an additional follow-up of 2 years after the enrollment of the last patient in order to show an absolute increase of 20% in EFS (from 40 to 60%) at 3 years, given 123 expected events (b ¼ 0.1; a ¼ 0.05). Within 4 years, 259 patients were evaluated. As of May 2005, 155 events had occurred with respect to EFS. CR proportion, tolerance and overall survival (OS) defined secondary end points. A third objective was to assess the relation between the defined prognostic subgroups and the outcome. OS was calculated from the date of first randomization. Toxicity and adverse events were classified according to the World Health Organization (WHO) criteria. 18 Assessment of comparability of characteristics for the randomized groups was evaluated by the Pearson's w 2 test. All tests were two sided with statistical significance set at 0.05. Statistical analyses were performed according to an intention-to-treat basis. Relapse was defined as a recurrence of leukemia after a first CR. EFS and OS distributions were estimated by the method of Kaplan-Meier. All comparisons were performed by the log-rank test. Simultaneous effects of multiple covariates were estimated with the maximum-likelihood logistic regression model for response and with the Cox's model for EFS and OS and tested by the likelihood ratio test, which was also used in univariate analyses for continuous variables. The following variables were included in the model: initial white blood cell (WBC) count, karyotype, age and arm of R1 (arm A vs B). Estimated odds or hazard ratios (HRs) are reported with 95% confidence intervals (CIs). Regarding the second randomization, four therapeutic strategies were individualized: no GM-CSF/EMA, no GM-CSF/CALGBlike, GM-CSF/EMA and GM-CSF/CALGB-like. The Cox's proportional hazards model was used to obtain the estimate and the 95% CI of the HR of one therapeutic strategy vs another therapeutic strategy. Analyses used a disjunctive coding allowing a one-to-one comparison with an a priori defined reference category. The Wald's test has been used to determine the prognostic significance. All computations were made using BMDP software (BMDP Statistical Software, Los Angeles, CA, USA).
Results
Patient population and characteristics
The first randomization began in April 1999 and ended in May 2003, with 262 patients included from 16 institutions. One patient was withdrawn (patient refusal) and two additional patients were ineligible because of misdiagnosis (secondary AML). Present results deal thus with 259 randomized patients (arm A with GM-CSF, 124 patients; arm B without GM-CSF, 135 patients). The median follow-up of this cohort was 3.2 years. Pretreatment characteristics are summarized in Table 1 . There were no main imbalances between the two randomization arms, including assignment to postremission chemotherapy. The median age was 27 years (range, 15-49 years). Cytogenetic analysis was performed in 253 patients (98%), but available in 228 (88%). Overall, 19% had favorable, 49% had intermediate and 23% had unfavorable cytogenetics. The cytogenetics of 9% was unknown (analysis not performed or failure).
During induction chemotherapy, GM-CSF was not given to two of the 124 patients who were assigned to receive GM-CSF. Treatment with GM-CSF was delayed (median, 2 days) in five patients and interrupted in 16 patients. The primary reasons for these deviations were related to intolerance or medical problems (52%), leukocytosis (26%) and investigator's mistakes. GM-CSF was not given, postponed or interrupted in 12 patients during consolidation chemotherapy (10 patients in the CALGBlike arm and two patients in the EMA arm) because of intolerance (nine patients), local investigator decision (two patients) or patient's refusal (one patient).
Overall treatment results
The overall CR proportion was 83% after induction therapy and 89% (230 of 259 patients) after salvage therapy. The 3-year EFS estimate was at 38% and the 3-year OS at 50%.
Induction results and toxicity according to randomization arm
After induction, the proportions of CR were 88 and 78% for patients receiving GM-CSF (arm A) and those not receiving GM-CSF (arm B) respectively (Po0.04). Treatment failure was observed in 9% of patients in the arm A and in 15% in the arm B, whereas death during induction was observed in 3 and 7% respectively. In a multivariable model including the arm of first randomization, initial WBC count and cytogenetics, administration of GM-CSF appeared as the only favorable prognostic factor for CR achievement after the first course of chemotherapy (arm A vs B; odds ratio, 3.33; 95% CI, (1.48-7.45); P ¼ 0.002). Eight patients received salvage therapy in the arm A and 15 in the arm B. Overall, the proportions of CR were 87% in the group that did not receive GM-CSF and 91% in the group that received GM-CSF (P ¼ 0.25) ( Table 2) .
Most patients were assessable for toxicity during induction chemotherapy. The frequencies of various severe (WHO grade X3) adverse effects after induction chemotherapy and the times to hematopoietic recovery were similar in the two groups Abbreviations: CR, complete remission; GM-CSF, granulocyte-macrophage colony-stimulating factor.
GM-CSF priming in younger adults with AML X Thomas et al (Table 3 ). Neutrophils recovered to more than 0.5 Â 10 9 /l at a median of 31 days (range, 0-69 days) after initiation of therapy. Platelets recovered to more than 50 Â 10 9 /l at a median of 39 days (range, 11-89 days). The mortality rate after induction7 salvage therapy was 6% (4% in the arm A and 7% in the arm B).
EFS and OS according to randomization arm
A comparison of the four therapeutic strategies following randomizations are given in Table 4 . The EFS rate at 3 years was higher in the GM-CSF group (arm A) than in the group that did not receive GM-CSF (arm B) (42 vs 34%; P ¼ 0.06) (Figure 2a) . At 3 years, there were no statistical differences between the two groups in the rates of OS (Figure 2b) . Ninetyone patients (39%) were excluded from the second randomization: 35 patients with matched-identical donor received allogeneic SCT according to protocol recommendations (19 patients from the arm A and 16 patients from the arm B), 11 patients with t(8;21) were systematically treated according to CALGB-like arm and 45 patients were excluded for other reasons. These reasons were severe toxicity during induction therapy resulting in poor physical condition (19 patients), medical decision (15 patients), patient refusal (seven patients) and early relapse (four patients). The proportion of patients who were excluded from the second randomization was similar in the group given GM-CSF (arm A) and the group not given GM-CSF (arm B) during induction. An analysis adjusted for patients not excluded from second randomization confirmed the superiority of the GM-CSF group.
The frequencies of severe adverse effects after consolidation therapy and the times to hematopoietic recovery after consolidation therapy did not differ significantly between arm A and arm B among the two arms of second randomization.
In a multivariable model including cytogenetics, initial WBC count, age and arm of first randomization, only karyotype risk group was of prognostic value for EFS (HR, 2.34; 95% CI, (1.75-3.14); Po0.0001)and OS (HR, 2.75; 95% CI, (1.98-3.80); Po0.0001). Abbreviations: CALGB, cancer and leukemia group B; CI, confidence interval; EMA, etoposide, mitoxantrone and cytarabine; GM-CSF, granulocyte-macrophage colony-stimulating factor. *A value 41 indicates that the outcome is worse in that category as compared with the baseline. **P-value given by the Wald's test.
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Prognostic subgroup analyses
No differences were found in terms of EFS for patients with favorable (P ¼ 0.08) or unfavorable (P ¼ 0.3) cytogenetics. However, a higher proportion rate of CR was observed in the arm A for patients with unfavorable cytogenetics (89 vs 67%; P ¼ 0.05).
Patients with intermediate-risk cytogenetics benefited from GM-CSF therapy (3-year EFS, 50 vs 35%, P ¼ 0.05) (Figure 3a) . The benefit of GM-CSF in patients with intermediate karyotype was in part related to a higher proportion rate of CR after the initial course of induction chemotherapy (91 vs 79%, P ¼ 0.06) and a lower rate of relapse (29 vs 47% at 3 years; P ¼ 0.05). However, GM-CSF did not significantly improve OS. The effect of GM-CSF in the intermediate cytogenetic group was confirmed when considering only patients following the second randomization (3-year EFS, 49 vs 31%, P ¼ 0.03; 3-year OS, 65 vs 43%, P ¼ 0.05) (Figure 3b ). GM-CSF also influenced favorably the intermediate group when considering our prognostic index, based on cytogenetics and the number of chemotherapy courses required for achieving CR (3-year EFS, 50 vs 34%, P ¼ 0.04; 3-year OS, 63 vs 44%, P ¼ 0.04) (Figure 3c) .
Comparisons between arms of second randomization according to the first randomization are given in Table 4 . EMA consolidation without GM-CSF administration represented the reference therapy to which the other treatments were compared (Table 4) . 1 When considering the intermediate-risk group, 3-year EFS was similar between the CALGB-like arm, irrespectively of the administration of GM-CSF (57 and 51% respectively) and the EMA arm with GM-CSF (55%), whereas a statistically significant difference was observed for patients randomized into the EMA consolidation arm who did not receive GM-CSF (3-year EFS, 23%) ( Figure 4 and Table 4 ). GM-CSF priming in younger adults with AML X Thomas et al
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Discussion
Priming with GM-CSF may modulate cell-cycle kinetics of leukemic blasts and render them more susceptible to phasespecific agents. 25 GM-CSF may, however, involve other mechanisms, including facilitation of intracellular uptake of 1-b-D-arabinofuranosyl-cytosine 5 0 -triphosphate, 6 alteration of bcl-2 protein expression after cytarabine-mediated generation of reactive oxygen intermediates, 26 stimulation of leukemic cell metabolism contributing to increase uptake and processing of cytarabine, 6 or enhancement of chemotherapy-induced apoptosis of leukemic blasts. 27 Our choice for this cytokine (regarded as the most toxic cytokine formulation used for AML) was motivated by our previous study in refractory or relapsing AML showing that time to progression tended to be longer in the GM-CSF group.
14 In contrast to our previous study, a placebocontrolled study was not, however, finally performed because of the presence of serum albumin into the placebo vials initially provided by Schering Plough in order to match with excipients of GM-CSF. Another problem arising during the study was that the production of GM-CSF was definitively stopped in 2003 preventing from completely meet our accrual target. GM-CSF is then no longer available in Europe or in the USA. Although different products may not be identical both in terms of toxicity and, possibly, efficacy, we strongly believe that priming with GM-CSF is fairly comparable with what could be observed after priming with other hematopoietic growth factors such as filgrastim, lenograstim or sargramostim products that are still available. Furthermore, to our knowledge, our study design was the only one including priming with the same growth factor in subsequent consolidation in those patients who received it during induction.
Priming benefited to patients as an outstanding CR proportion was observed after the initial induction chemotherapy in patients primed with GM-CSF. A difference was also observed in terms of EFS with 3-year EFS at 42% for patients receiving GM-CSF vs only 34% for those without GM-CSF. The difference in EFS probability resulted from GM-CSF-mediated activation of subpopulations of leukemic cells that were initially sensitive to cytarabine. Increased levels of active metabolites of cellcycle-dependent agents and increased killing of leukemic progenitors by the drug have been shown in vitro. [2] [3] [4] [5] [6] 28 Adherence to GM-CSF treatment was good. Treatment was not given, delayed or interrupted in only 18% mainly because of hyperleukocytosis. Cytogenetics is known as the most important prognostic factor in younger adults. 29, 30 Our results were therefore interpreted regarding cytogenetic data. It appeared that mainly patients with intermediate-risk cytogenetics significantly benefited from GM-CSF therapy in terms of EFS. This was confirmed when considering only patients following the second randomization or subgroups defined according to our prognostic index. The absence of significant difference in patients with favorable cytogenetics might indicate that the combination therapy was optimal in terms of its ability to kill leukemic cells in this subgroup. There was also a lower benefit in patients with unfavorable cytogenetics. This could be explained by the high rate of early relapse translating into no benefit of priming. However, we wonder whether data were really sufficient to make such statements. In our study, the statistical power was initially based on getting 344 patients without any allowance for different subtypes of AML. The absence of significant difference between arm A and arm B could simply be related to the small number of patients in each subgroup.
TSC principle was to recruit leukemic cells in the cell cycle using a first sequence of chemotherapy and to administer the second sequence at the presumed time of peak cell recruitment induced by the first sequence to maximize leukemic cell kill by cytotoxic agents. TSC seemed ideally suited to be associated with hematopoietic growth factor therapy as its efficacy is believed to directly rely to the increase in S-phase cells before the second sequence of chemotherapy. This was confirmed by the significant difference observed between arm A and arm B in terms of CR achievement after the first course of TSC induction. Furthermore for intermediate cytogenetics, GM-CSF treatment brought the 3-year EFS rate in the timed-sequential consolidation up to that noted with high-dose cytarabine. Few other prospective trials of priming with GM-CSF have been conducted. Three large randomized studies have used GM-CSF concomitantly with and after chemotherapy. [11] [12] [13] However, these studies involved older patients, most of them had an unfavorable prognosis. Priming for 48 h with GM-CSF before chemotherapy did not show a sufficient effect on S-phase percentage to translate into a clinical impact. 13 Furthermore, it was not possible to clearly distinguish the effect of priming from those of enhanced hematopoietic recovery. 11, 12 However, in one study, 12 a difference was noted in terms of disease-free survival, with a trend to improve OS, features that could be considered likely to be owing to priming. We previously demonstrated in relapsed patients that the addition of GM-CSF to TSC actually enhanced the in vivo recruitment of quiescent leukemic blasts into the cell cycle, resulting in a trend to a longer time to progression, but priming was limited to the 4-day interval between the two sequences of the induction phase. 14 Another study focused on the effect of growth-factor priming in first-line therapy, but it was conducted in young and middleaged adults and used G-CSF as priming factor.
9 G-CSF improved OS and DFS in the group with standard risk AML. As in our study, there was no indication that priming improved the outcome among patients with favorable and those with unfavorable AML, but stimulation of leukemia was not a clinical problem in those cases.
Our results show that chemotherapy and sensitization of leukemic cells by hematopoietic growth factors is a plausible strategy for improving the outcome in newly diagnosed AML, particularly for those displaying intermediate cytogenetics. Laboratory correlative studies are warranted to identify the biological factor most important in the improved outcome of these patients. 
